Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Azacitidine-Based Combinations Represent New Treatment Possibilities in MDS

November 2nd 2022

Mikkael A. Sekeres, MD, MS, discussed the changes to the classifications of MDS, the evolution of targeted therapies for patients with acute myeloid leukemia, and approaches for patients with bone marrow failure syndromes.

First Patient Dosed With Menin Inhibitor BMF-219 in COVALENT-101 Trial in CLL

November 1st 2022

The first patient in the chronic lymphocytic leukemia cohort has been dosed in the phase 1 COVALENT-101 trial, which is evaluating the first-in-class covalent menin inhibitor BMF-219.

FDA Grants Fast Track Designation to MT-101 for CD5+ Relapsed/Refractory PTCL

October 31st 2022

The FDA has granted a fast track designation to MT-101 for use as a potential therapeutic option in patients with relapsed or refractory, CD5-positive peripheral T-cell lymphoma.

Iomab-B Conditioning Elicits Durable CR in Relapsed/Refractory AML

October 31st 2022

Reduced-intensity conditioning treatment plus Iomab-B prior to bone marrow transplant led to a durable and statistically significant 6-month complete remission rate vs conventional care in older patients with active, relapsed/refractory acute myeloid leukemia.

Women in Oncology: Leaving Passionate Legacies

October 28th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the scientific achievements they have witnessed in the field of leukemia and their hopes for the future of treating this disease.

Women in Oncology: The Value of Female Leadership

October 28th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss how they turned career obstacles into opportunities and what they have learned from being women in the leukemia field.

Cilta-cel Induces Strong Response in Chinese Patients With Relapsed/Refractory Multiple Myeloma

October 28th 2022

Ciltacabtagene autoleucel produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma treated at 8 sites in China.

Women in Oncology: Opportunities for Success Through Mentorship

October 27th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the importance of strong mentorship relationships and the unique growth opportunities they found at different points of their careers.

Women in Oncology: Actively Preparing for Advances in Leukemia Treatment

October 27th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the toughest challenges they faced in the leukemia field at the start of their fellowships and careers.

FDA Grants Priority Review to Quizartinib for Newly Diagnosed FLT3-ITD–Positive AML

October 24th 2022

The FDA has accepted and granted priority review to the new drug application for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of newly diagnosed adult patients with FLT3-ITD–positive acute myeloid leukemia.

Dr. Chen on FLASH Trial Results in CTCL

October 21st 2022

Pei-Ling Chen, MD, PhD, gives her perspective on results from the phase 3 FLASH trial investigating synthetic hypericin in CTCL.

Dr. Chen Explores Possible Genomic Basis for Racial Disparities in CTCL Outcomes

October 21st 2022

Pei-Ling Chen, MD, PhD, discusses genomic findings that may explain poorer outcomes for Black patients with CTCL.

Dr. Chen on Identifying Malignant T-Cell Signatures in CTCL

October 21st 2022

Pei-Ling Chen, MD, PhD, discusses findings from a study the multiomics of patients with transformed CTCL that she led at Moffitt Cancer Center.

Dr. Chen Discusses Management of Early Stage, Advanced CTCL

October 21st 2022

Pei-Ling Chen, MD, PhD, says management of cutaneous T-cell lymphoma requires a multidisciplinary team of specialists including dermatologists and radiation oncologists.

Dr. Chen Discusses Racial Disparities in CTCL

October 21st 2022

Pei-Ling Chen, MD, PhD, discusses epidemiology and racial disparities in CTCL.

Dr. Chen Highlights Incidence of CTCL

October 21st 2022

Pei-Ling Chen, MD, PhD, discusses the incidence of CTCL.

Leukemia Experts Discuss Early Career Growth, Mentorship, and Gender Bias in Academia

October 20th 2022

Drs DiNardo, Wang, and Altman discuss the challenges they faced in their early careers, the rollout of molecular profiling and targeted therapy in the early 2000s, and their growth from protégés to mentors.

Novel Treatments Begin to Rival Transplant in AML and DLBCL

October 18th 2022

Farrukh Awan, MD, discusses transplant and chemotherapy options in frontline diffuse large B-cell lymphoma, the emergence of CAR T-cell therapy in relapsed diffuse large B-cell lymphoma, and available targeted therapies in acute myeloid leukemia.

European Commission Approves Second-line Axi-cel for DLBCL/HGBL

October 18th 2022

The European Commission has approved axicabtagene ciloleucel for the treatment of adult patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Treatments Branch Out in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

October 18th 2022

Peter Voorhees, MD, highlights important topics that his colleagues discussed at the meeting, including the important role of up-front autologous stem cell transplant and distinct adverse effects to be aware of when using different CAR T-cell therapies.